Comparison of the discriminative stimulus effects of midazolam after intracranial and peripheral administration in the rat

Christine A. Sannerud, Nancy A Ator, Roland R Griffiths

Research output: Contribution to journalArticle

Abstract

Rats were trained in a two-lever drug discrimination paradigm to discriminate midazolam (0.32 mg/kg, i.p. or 1.0 mg/kg, i.p.) from the no-drug condition. After completion of i.p. and s.c. midazolam generalization gradients (0.032-1.0 mg/kg), rats were surgically implanted with unilateral cannulae into the lateral ventricles. Intracerebroventricular (i.c.v.) doses of 1.1-44.2 μg midazolam were delivered to unrestrained rats. Midazolam produced dose-dependent increases in drug-appropriate responding by all three routes of administration, but was 2.4- to 4.3-fold more potent when given i.c.v. than when given s.c. or i.p. Midazolam, over the dose range tested, did not produce substantial decreases in response rate by any route of administration. The discriminative-stimulus effect of i.c.v. midazolam was blocked by peripherally administered flumazenil, and such antagonism was surmounted by a 2- to 5-fold increase in the i.c.v. midazolam dose. Taken together, these data suggest that the discriminative-stimulus effects of midazolam are mediated via central benzodiazepine (BZ) receptors.

Original languageEnglish (US)
Pages (from-to)261-268
Number of pages8
JournalLife Sciences
Volume49
Issue number4
DOIs
StatePublished - 1991

Fingerprint

Midazolam
Rats
Pharmaceutical Preparations
Flumazenil
Lateral Ventricles
GABA-A Receptors

ASJC Scopus subject areas

  • Pharmacology

Cite this

Comparison of the discriminative stimulus effects of midazolam after intracranial and peripheral administration in the rat. / Sannerud, Christine A.; Ator, Nancy A; Griffiths, Roland R.

In: Life Sciences, Vol. 49, No. 4, 1991, p. 261-268.

Research output: Contribution to journalArticle

@article{23737696e127409b82a43353e3f4ce50,
title = "Comparison of the discriminative stimulus effects of midazolam after intracranial and peripheral administration in the rat",
abstract = "Rats were trained in a two-lever drug discrimination paradigm to discriminate midazolam (0.32 mg/kg, i.p. or 1.0 mg/kg, i.p.) from the no-drug condition. After completion of i.p. and s.c. midazolam generalization gradients (0.032-1.0 mg/kg), rats were surgically implanted with unilateral cannulae into the lateral ventricles. Intracerebroventricular (i.c.v.) doses of 1.1-44.2 μg midazolam were delivered to unrestrained rats. Midazolam produced dose-dependent increases in drug-appropriate responding by all three routes of administration, but was 2.4- to 4.3-fold more potent when given i.c.v. than when given s.c. or i.p. Midazolam, over the dose range tested, did not produce substantial decreases in response rate by any route of administration. The discriminative-stimulus effect of i.c.v. midazolam was blocked by peripherally administered flumazenil, and such antagonism was surmounted by a 2- to 5-fold increase in the i.c.v. midazolam dose. Taken together, these data suggest that the discriminative-stimulus effects of midazolam are mediated via central benzodiazepine (BZ) receptors.",
author = "Sannerud, {Christine A.} and Ator, {Nancy A} and Griffiths, {Roland R}",
year = "1991",
doi = "10.1016/0024-3205(91)90012-Z",
language = "English (US)",
volume = "49",
pages = "261--268",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Comparison of the discriminative stimulus effects of midazolam after intracranial and peripheral administration in the rat

AU - Sannerud, Christine A.

AU - Ator, Nancy A

AU - Griffiths, Roland R

PY - 1991

Y1 - 1991

N2 - Rats were trained in a two-lever drug discrimination paradigm to discriminate midazolam (0.32 mg/kg, i.p. or 1.0 mg/kg, i.p.) from the no-drug condition. After completion of i.p. and s.c. midazolam generalization gradients (0.032-1.0 mg/kg), rats were surgically implanted with unilateral cannulae into the lateral ventricles. Intracerebroventricular (i.c.v.) doses of 1.1-44.2 μg midazolam were delivered to unrestrained rats. Midazolam produced dose-dependent increases in drug-appropriate responding by all three routes of administration, but was 2.4- to 4.3-fold more potent when given i.c.v. than when given s.c. or i.p. Midazolam, over the dose range tested, did not produce substantial decreases in response rate by any route of administration. The discriminative-stimulus effect of i.c.v. midazolam was blocked by peripherally administered flumazenil, and such antagonism was surmounted by a 2- to 5-fold increase in the i.c.v. midazolam dose. Taken together, these data suggest that the discriminative-stimulus effects of midazolam are mediated via central benzodiazepine (BZ) receptors.

AB - Rats were trained in a two-lever drug discrimination paradigm to discriminate midazolam (0.32 mg/kg, i.p. or 1.0 mg/kg, i.p.) from the no-drug condition. After completion of i.p. and s.c. midazolam generalization gradients (0.032-1.0 mg/kg), rats were surgically implanted with unilateral cannulae into the lateral ventricles. Intracerebroventricular (i.c.v.) doses of 1.1-44.2 μg midazolam were delivered to unrestrained rats. Midazolam produced dose-dependent increases in drug-appropriate responding by all three routes of administration, but was 2.4- to 4.3-fold more potent when given i.c.v. than when given s.c. or i.p. Midazolam, over the dose range tested, did not produce substantial decreases in response rate by any route of administration. The discriminative-stimulus effect of i.c.v. midazolam was blocked by peripherally administered flumazenil, and such antagonism was surmounted by a 2- to 5-fold increase in the i.c.v. midazolam dose. Taken together, these data suggest that the discriminative-stimulus effects of midazolam are mediated via central benzodiazepine (BZ) receptors.

UR - http://www.scopus.com/inward/record.url?scp=0025850559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025850559&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(91)90012-Z

DO - 10.1016/0024-3205(91)90012-Z

M3 - Article

C2 - 1649362

AN - SCOPUS:0025850559

VL - 49

SP - 261

EP - 268

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 4

ER -